Details for Patent: 8,550,073
✉ Email this page to a colleague
Which drugs does patent 8,550,073 protect, and when does it expire?
Patent 8,550,073 protects ONZETRA XSAIL and XHANCE and is included in two NDAs.
This patent has five patent family members in three countries.
Summary for Patent: 8,550,073
| Title: | Nasal delivery |
| Abstract: | A nasal delivery device for and method of delivering substance to a nasal cavity of a subject, the delivery device comprising: a nosepiece unit (20, 24) including a nosepiece (17) for fitting to a nostril of a subject and a nozzle (45) through which substance is in use delivered, preferably substantially axially to a longitudinal axis of the nosepiece, to the respective nasal cavity, wherein at least a tip element of the nosepiece has, at least in one configuration, an elongate lateral section which has a longer dimension in a first, sagittal direction than a second direction orthogonal to the sagittal direction, such that, when the nosepiece is inserted in the nasal cavity of the subject, the longer dimension of the nosepiece acts to engage lower and upper surfaces of the nasal cavity, preferably at the nasal valve, and expand the same in the sagittal plane; and a delivery unit (43, 49, 51) for delivering substance through the nozzle of the nosepiece. |
| Inventor(s): | Djupesland; Per Gisle (Oslo, NO) |
| Assignee: | OptiNose AS (Oslo, NO) |
| Application Number: | 12/281,894 |
|
Patent Claim Types: see list of patent claims | Delivery; Device; Use; |
Drugs Protected by US Patent 8,550,073
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Currax | ONZETRA XSAIL | sumatriptan succinate | POWDER;NASAL | 206099-001 | Jan 27, 2016 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Optinose Us Inc | XHANCE | fluticasone propionate | SPRAY, METERED;NASAL | 209022-001 | Sep 18, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,550,073
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| United Kingdom | 0604444.0 | Mar 6, 2006 |
| PCT Information | |||
| PCT Filed | March 06, 2007 | PCT Application Number: | PCT/IB2007/001709 |
| PCT Publication Date: | September 13, 2007 | PCT Publication Number: | WO2007/102089 |
International Family Members for US Patent 8,550,073
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1996266 | ⤷ Sign Up | |||
| United Kingdom | 0604444 | ⤷ Sign Up | |||
| United Kingdom | 0704302 | ⤷ Sign Up | |||
| United Kingdom | 2435835 | ⤷ Sign Up | |||
| World Intellectual Property Organization (WIPO) | 2007102089 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
